Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage

Gastroenterology

Volumn 123, Issue 5, 2002, Pages 1598-1606

  Fiorucci, Stefano ^a   De Lima, Octavio Menezes ^a,b   Mencarelli, Andrea ^a   Palazzetti, Barbara ^a   Distrutti, Eleonora ^a   Dicay, Michael ^b   Ma, Li ^b   Romano, Mario ^c   Morelli, Antonio ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; LIPOXIN A; ROFECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ACETYLATION; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; GASTRITIS; LEUKOCYTE ADHERENCE; MALE; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STOMACH INJURY; STOMACH MUCOSA; STOMACH PROTECTION;

EID: 0036828285     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36558     Document Type: Article

References (29)

1. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
2. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
3. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-397.
4. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff T, Flogerzi B, Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Br J Pharmacol 1998;123:795-804.
5. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 1999;128:1659-1666.
6. Davies NM, Sharkey KA, Asfaha S, MacNaughton WK, Wallace JL. Aspirin induces a rapid up-regulation of cyclooxygenase-2 expression in the rat stomach. Aliment Pharmacol Ther 1997;11:1101-1108.
7. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 1998;123:927-935.
8. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992;267:12387-12392.
9. Mancini JA, O'Neill GP, Bayly C, Vickers PJ. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetlylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett 1994;342:33-37.
10. Claria J, Serhan CN. Aspirin triggers previously unrecognized bioactive eicosanoids in human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995;92:9475-9479.
11. Serhan CN, Oliw E. Unorthodox routes to prostanoid formation: New twists in cyclooxygenase-initiated pathways. J Clin Invest 2001;107:1481-1489.
12. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by non-steroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990;259:G462-G467.
13. Asako H, Kubes P, Wallace JL, Wolf RE, Granger DN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology 1992;103:146-152.
14. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclooxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999;126:1200-1204.
15. Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, Testa R. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999;9:1773-1778.
16. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazo-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
17. 4 ELISA. J Pharmacol Exp Ther 1998;287:779-790.
18. Romano M, Serhan CN. LX generation by permeabilize human platelets. Biochemistry 1992;31:8269-8277.
19. MacNaughton WK, Cushing K. Role of constitutive cyclooxygenase-2 in prostaglandin-dependent secretion in mouse colon in vitro. J Pharmacol Exp Ther 2000;293:539-544.
20. Perretti M, Getting SJ, Solito E, Murphy PM, Gao JL. Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics. Am J Pathol 2001;158:1969-1973.
21. Wallace JL, McKnight GW, Miyasaka M, Tamatani T, Pauson J, Anderson DC, Granger DN, Kubes P. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol 1993;265:G993-G998.
22. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000;284:1247-1255.
23. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MD, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
24. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol 2001;132:1565-1573.
25. Tanaka A, Araki H, Komoike Y, Hase S, Takeuchi K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris 2001;95:21-27.
26. Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors. J Exp Med 1997;185:1693-1704.
27. Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991;100:878-883.
28. 2. Intravenous, oral and intrajejunal administration. Gastroenterology 1976;70:359-370.
29. 4 receptor that is regulated by interleukin (IL)-13 and interferon γ and inhibits tumor necrosis factor-α-induced IL-8 release. J Exp Med 1998;187:1285-1294.